Mannose-decorated ginsenoside Rb1 albumin nanoparticles for targeted anti-inflammatory therapy.

Frontiers in Bioengineering and Biotechnology Pub Date : 2022-08-15 eCollection Date: 2022-01-01 DOI:10.3389/fbioe.2022.962380

Zhihui Fu, Xiaohui Wang, Xuan Lu, Ying Yang, Lingling Zhao, Lin Zhou, Kaikai Wang, Hanlin Fu

{"title":"Mannose-decorated ginsenoside Rb1 albumin nanoparticles for targeted anti-inflammatory therapy.","authors":"Zhihui Fu, Xiaohui Wang, Xuan Lu, Ying Yang, Lingling Zhao, Lin Zhou, Kaikai Wang, Hanlin Fu","doi":"10.3389/fbioe.2022.962380","DOIUrl":null,"url":null,"abstract":"<p><p>Ginsenoside Rb1 is a potential anti-inflammatory natural molecule, but its therapeutic efficacy was tremendously hampered by the low solubility and non-targeted delivery. In this study, we innovatively developed a mannose (Man)-modified albumin bovine serum albumin carrier (Man-BSA) to overcome the previously mentioned dilemmas of Rb1. The constructed Man-BSA@Rb1 NPs could improve the solubility and increase the cellular uptake of Rb1, finally leading to the enhanced anti-inflammatory effects. The robust therapeutics of Man-BSA@Rb1 NPs were measured in terms of nitrite, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) levels, which might be achieved by potently inhibiting nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways in lipopolysaccharide (LPS)-induced Raw264.7 cells. Moreover, the therapeutic efficacy of Man-BSA@Rb1 NPs was further confirmed in the d-Gal/LPS-induced liver injury model. The results indicated that Man-BSA may offer a promising system to improve the anti-inflammatory therapy of Rb1.</p>","PeriodicalId":508781,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":" ","pages":"962380"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420840/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2022.962380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Ginsenoside Rb1 is a potential anti-inflammatory natural molecule, but its therapeutic efficacy was tremendously hampered by the low solubility and non-targeted delivery. In this study, we innovatively developed a mannose (Man)-modified albumin bovine serum albumin carrier (Man-BSA) to overcome the previously mentioned dilemmas of Rb1. The constructed Man-BSA@Rb1 NPs could improve the solubility and increase the cellular uptake of Rb1, finally leading to the enhanced anti-inflammatory effects. The robust therapeutics of Man-BSA@Rb1 NPs were measured in terms of nitrite, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) levels, which might be achieved by potently inhibiting nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways in lipopolysaccharide (LPS)-induced Raw264.7 cells. Moreover, the therapeutic efficacy of Man-BSA@Rb1 NPs was further confirmed in the d-Gal/LPS-induced liver injury model. The results indicated that Man-BSA may offer a promising system to improve the anti-inflammatory therapy of Rb1.

Abstract Image

查看原文本刊更多论文

甘露糖修饰的人参皂苷Rb1白蛋白纳米颗粒靶向抗炎治疗。

人参皂苷Rb1是一种潜在的抗炎天然分子，但由于其溶解度低和非靶向递送，极大地影响了其治疗效果。在这项研究中，我们创新地开发了甘露糖(Man)修饰白蛋白牛血清白蛋白载体(Man- bsa)，以克服上述Rb1的困境。构建的Man-BSA@Rb1 NPs可以提高Rb1的溶解度，增加Rb1的细胞摄取，最终增强抗炎作用。通过亚硝酸盐、肿瘤坏死因子-α (TNF-α)和白细胞介素-6 (IL-6)水平来衡量Man-BSA@Rb1 NPs的稳健治疗效果，这可能是通过在脂多糖(LPS)诱导的Raw264.7细胞中有效抑制核因子-κB (NF-κB)和丝裂原活化蛋白激酶(MAPK)信号通路来实现的。此外，Man-BSA@Rb1 NPs的治疗效果在d-Gal/ lps诱导的肝损伤模型中得到进一步证实。结果表明，Man-BSA可能为改善Rb1的抗炎治疗提供了一个有希望的系统。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology

自引率

0.00%

发文量